Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol

A Sequential Dose Cohort Pharmacokinetic and Safety Study of Implantable Long-Acting Naltrexone Subcutaneous Pellets With or Without Bupropion Compared to Naltrexone IM Injection (Vivitrol®) in Healthy Normal Volunteers

Naltrexone (NTX), an opioid receptor antagonist, has a longstanding history of safe and effective use for the treatment of addictive disorders. NTX is available in several forms, such as daily oral tablets (Revia®) and sustained release monthly injections (Vivitrol®). BioCorRx Pharmaceuticals is currently developing a subcutaneous implantable pellet drug product, BICX104, which contains NTX base anhydrous (997.5 mg) and can be administered via a minor surgical procedure. BICX104 is anticipated to provide plasma concentrations of ≥ 1 ng/mL NTX for 3 months.

Subjects will be enrolled in 4 sequential cohorts and followed for a total of 196 days, comprising an 84-day treatment period, an 84-day follow-up period, and a 28-day post-treatment follow-up period. While therapeutic levels of naltrexone ( ≥ 1 ng/mL plasma concentration) are expected to be maintained throughout the treatment period, intermittent PK sampling will continue through Day 196, at which all subjects are expected to achieve NTX levels below the level of quantitation (BLQ). Safety parameters include assessment of adverse events, vital signs, laboratory parameters, ECG data, and the Columbia Suicide Severity Rating Scale (C-SSRS), and will continue through the final safety visit at Day 196.

A total of 30 healthy normal volunteers will be enrolled sequentially in the following cohorts, listed in sequence:

1. One BICX104 (1.0 g NTX) implantable pellet (n = 8)
2. One BICX104 implantable pellet with 450 mg QD bupropion XL (n = 8)
3. Two BICX104 implantable pellets with 450 mg QD bupropion XL (n = 8)
4. Three consecutive Vivitrol 380 mg injections Q28 days (n = 6) Enrollment will be stratified by biological sex (50% females and 50% males in each cohort)

Subjects will participate in 18 clinic visits over 31 weeks comprising the 3-week screening period, 12-week treatment period, 12-week follow-up period, and 4-week safety follow-up period.

The test products will be BICX104 implantable pellets (dosage: 1 or 2 implants q. 12 weeks), Bupropion XL (dosage: 450 mg QD)

BICX104 will be supplied to the clinical research site in appropriately labeled closed containers; bupropion XL will be supplied in its standard commercial packaging configuration.

The comparator product will be Vivitrol® IM injection (380 mg NTX) (dosage: 1 injection q. 4 weeks) Vivitrol® will be supplied in its standard commercial packaging configuration.

The study assessments will be as follows:

After all screening assessments and the 24-hour Treatment Initiation Visit, safety and PK assessments will occur on Days 3, 5, 7, 14, 21, 28, 42, 56, 70, 84, 98, 112, 126, 140, 154, and 168. Final safety assessments will occur on Day 196. The Treatment Initiation Visit will involve 1 overnight stay and include PK sampling at pre-dose, and 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 hours post-dose, in addition to safety assessments.

Safety assessments will include clinical chemistry, hematology, vital signs, physical exam, ECGs, and administration of the Columbia Suicide Severity Rating Scale (C-SSRS).

Study Overview

• Status: Recruiting
• Conditions: Healthy Adult Male and Female Volunteers
• Intervention / Treatment: Drug: BICX104 naltrexone implantable pellet; Drug: Bupropion 150 mg XL; Drug: Naltrexone (depot)

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Study Recruitment Inquiries, Segal Trials; Phone Number: 877-734-2588; Email: studyinquiries@segaltrials.com

Study Locations

• United States
  • Florida
    • Miami, Florida, United States, 33106
      • Recruiting
      • Study Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Willing and able to provide informed consent and to read and understand study documents in English or Spanish
2. Female or male subjects aged 18-65 years old
3. In good health, as determined by the study physician, based on complete medical history, physical examination, vital signs measurement, ECG, and laboratory tests within normal ranges, to permit treatment.
4. Meet subjective and objective measures of being opioid-free prior to study treatment initiation, including negative urine drug screen results at screening and enrollment.
5. BMI of 18.5 to 30.0 kg/m2, inclusive.
6. Must agree to comply with all study requirements and be willing to complete entire study.
7. Persons of childbearing potential agree to use acceptable birth control methods and have periodic urine pregnancy testing done during participation in the study

Exclusion Criteria:

1. Have a history of any psychiatric disorder OR suicidal ideation, behavior, or risk of self-harm as evidenced by endorsement of items 2, 3, 4, or 5 on the C-SSRS
2. Have a history of angle-closure glaucoma
3. Have a history of epilepsy, seizure disorder, or head trauma with neurological sequelae (e.g., loss of consciousness that required hospitalization); current anorexia nervosa or bulimia; or any other conditions that increase seizure risk in the opinion of the study medical clinician
4. Have evidence of second or third degree heart block, atrial fibrillation, atrial flutter, prolongation of the QTc interval (> 450 in males or > 470 in females), or any other finding on the screening ECG that, in the opinion of the study medical clinician, would preclude safe participation in the study
5. Have Stage 2 hypertension as determined by the study medical clinician (e.g., greater than or equal to 160/100 in 2 out of 3 readings during screening)
6. Have any elevated bilirubin test value, or AST, ALT or alkaline phosphatase > 1.5 times the upper limit of normal, per laboratory criteria
7. Have a platelet count <100 x 103/μL; known coagulopathy, or need for anticoagulant therapy during the study
8. Have a known allergy or sensitivity to bupropion, naltrexone, or magnesium stearate, or any topical antiseptics or local anesthetics to be used in the implant procedure.
9. Have taken an investigational drug in another study within 30 days of study consent
10. Have a history of any substance abuse disorder, have been prescribed and taken naltrexone or bupropion within 30 days of study consent, or have been administered Vivitrol® within 60 days of study consent
11. Be receiving ongoing treatment with antidepressants, xanthines (i.e., theophylline and aminophylline), systemic corticosteroids, nelfinavir, efavirenz, chlorpromazine, MAOIs, central nervous system stimulants (e.g., Adderall, Ritalin, etc.), or any medication that, in the judgment of the study medical clinician, could interact adversely with study medications
12. Have a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use which would preclude safe participation in the study as determined by the study medical clinician
13. Require treatment with opioid-containing medications (e.g., opioid analgesics) during the study period
14. Have a surgery planned or scheduled during the study period
15. Are currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or other situation (e.g., unstable living arrangements) that could prevent participation in the study or in any study activities
16. Is prone to skin rashes, keloid scars, or irritation, or has a chronic skin condition or any other condition which might predispose them to adverse reactions to the implant procedure.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BICX104 (1 Pellet); 1 naltrexone implantable pellet	Drug: BICX104 naltrexone implantable pellet; BICX104 naltrexone implantable pellet
Experimental: BICX104 (1 Pellet) + bupropion XL 450 mg QD; 1 naltrexone implantable pellet + daily oral bupropion extended release 450 mg QD	Drug: BICX104 naltrexone implantable pellet; BICX104 naltrexone implantable pellet; Drug: Bupropion 150 mg XL; Extended release bupropion
Experimental: BICX104 (2 Pellets) + bupropion XL 450 mg QD; 2 naltrexone implantable pellets + daily oral bupropion extended release 450 mg QD	Drug: BICX104 naltrexone implantable pellet; BICX104 naltrexone implantable pellet; Drug: Bupropion 150 mg XL; Extended release bupropion
Active Comparator: Vivitrol q 28 days; Naltrexone intramuscular injection once every 28 days X 3	Drug: Naltrexone (depot); Vivitrol naltrexone intramuscular injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax	Maximum plasma concentration for naltrexone and 6-beta-naltrexol	From enrollment through Day 196 (28 Weeks)
Tmax	Time to reach maximum plasma concentration for naltrexone and 6-beta-naltrexol	From enrollment through Day 196 (28 Weeks)
AUC	Area under the concentration-time curve for naltrexone and 6-beta-naltrexol	From enrollment through Day 196 (28 Weeks)
Tlast	Time to reach the last quantifiable plasma concentration for naltrexone and 6-beta-naltrexol	From enrollment through Day 196 (28 Weeks)
Tlast ≥ 1 ng/mL	Time to reach the last quantifiable plasma concentration that is greater than or equal to 1 ng/mL for naltrexone	From enrollment through Day 196 (28 Weeks)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events (AEs)	Incidence and severity of adverse events	From enrollment through Day 196 (28 weeks)

Collaborators and Investigators

• Sponsor: BioCorRx Pharmaceuticals Inc
• Collaborators: National Institute on Drug Abuse (NIDA)

Study record dates

Study Major Dates

• Study Start (Actual): March 16, 2026
• Primary Completion (Estimated): December 5, 2026
• Study Completion (Estimated): December 5, 2026

Study Registration Dates

• First Submitted: September 26, 2025
• First Submitted That Met QC Criteria: November 25, 2025
• First Posted (Actual): December 8, 2025

Study Record Updates

• Last Update Posted (Actual): May 13, 2026
• Last Update Submitted That Met QC Criteria: May 12, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Safety; Naltrexone; Opioid Use Disorder (OUD); Pharmacokinetics (PK); Alcohol Use Disorder (AUD); Healthy Normal Volunteers; Methamphetamine Use Disorder (MUD)
• Additional Relevant MeSH Terms: Narcotic-Related Disorders; Mental Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Alcohol-Related Disorders; Opioid-Related Disorders; Alcoholism; Organic Chemicals; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Alkaloids; Polycyclic Aromatic Hydrocarbons; Polycyclic Compounds; Heterocyclic Compounds, 4 or More Rings; Naloxone; Morphinans; Opiate Alkaloids; Heterocyclic Compounds, Bridged-Ring; Phenanthrenes; Ketones; Propiophenones; Naltrexone; Bupropion
• Other Study ID Numbers: BICX-25-01b; U01DA059994-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: IPD will not be shared to protect the confidentiality of study participants.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No